Humana Inc. (NYSE:HUM – Get Rating) – Analysts at Oppenheimer dropped their Q3 2023 EPS estimates for Humana in a research report issued to clients and investors on Wednesday, February 1st. Oppenheimer analyst M. Wiederhorn now forecasts that the insurance provider will post earnings per share of $7.22 for the quarter, down from their prior estimate of $7.64. The consensus estimate for Humana's current full-year earnings is $28.00 per share. Oppenheimer also issued estimates for Humana's FY2023 earnings at $28.05 EPS, Q2 2024 earnings at $9.59 EPS, Q3 2024 earnings at $8.62 EPS, Q4 2024 earnings at $3.71 EPS, FY2024 earnings at $32.14 EPS and FY2025 earnings at $37.21 EPS.
Get
Humana alerts:
Other equities research analysts have also issued reports about the stock. The Goldman Sachs Group upgraded shares of Humana from a "neutral" rating to a "buy" rating and increased their target price for the stock from $575.00 to $652.00 in a report on Tuesday, December 13th. Cowen increased their target price on shares of Humana from $547.00 to $647.00 in a report on Monday, November 7th. UBS Group cut their target price on shares of Humana from $645.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday. SVB Leerink increased their target price on shares of Humana from $540.00 to $640.00 and gave the stock an "outperform" rating in a report on Thursday, November 3rd. Finally, Mizuho increased their target price on shares of Humana from $529.00 to $615.00 and gave the stock a "buy" rating in a report on Thursday, November 10th. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Humana currently has a consensus rating of "Moderate Buy" and an average price target of $607.65.
Humana Price Performance
Shares of HUM stock opened at $476.57 on Friday. Humana has a 52-week low of $408.20 and a 52-week high of $571.30. The stock has a market cap of $60.33 billion, a PE ratio of 21.62, a PEG ratio of 1.30 and a beta of 0.72. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.35 and a current ratio of 1.52. The firm's 50 day moving average price is $510.69 and its two-hundred day moving average price is $505.89.
Humana (NYSE:HUM – Get Rating) last announced its quarterly earnings data on Wednesday, February 1st. The insurance provider reported $1.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.46 by $0.16. Humana had a net margin of 3.02% and a return on equity of 20.50%. The firm had revenue of $22.44 billion for the quarter, compared to analysts' expectations of $22.45 billion. During the same period last year, the firm earned $1.24 earnings per share. The business's revenue for the quarter was up 6.6% on a year-over-year basis.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of HUM. Castleview Partners LLC boosted its holdings in shares of Humana by 46,704.0% during the 2nd quarter. Castleview Partners LLC now owns 11,701 shares of the insurance provider's stock worth $25,000 after buying an additional 11,676 shares during the period. Jones Financial Companies Lllp bought a new stake in shares of Humana during the 2nd quarter worth about $29,000. Arlington Partners LLC bought a new stake in shares of Humana during the 4th quarter worth about $29,000. WFA of San Diego LLC bought a new stake in shares of Humana during the 2nd quarter worth about $30,000. Finally, U.S. Capital Wealth Advisors LLC acquired a new stake in Humana in the 4th quarter worth about $35,000. Institutional investors own 93.38% of the company's stock.
Insider Buying and Selling at Humana
In other Humana news, CEO Bruce D. Broussard sold 7,000 shares of Humana stock in a transaction on Monday, December 12th. The shares were sold at an average price of $531.92, for a total value of $3,723,440.00. Following the sale, the chief executive officer now directly owns 65,602 shares in the company, valued at approximately $34,895,015.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Timothy S. Huval sold 635 shares of Humana stock in a transaction dated Friday, December 16th. The shares were sold at an average price of $497.71, for a total value of $316,045.85. Following the completion of the transaction, the insider now owns 4,968 shares of the company's stock, valued at approximately $2,472,623.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Bruce D. Broussard sold 7,000 shares of Humana stock in a transaction dated Monday, December 12th. The shares were sold at an average price of $531.92, for a total transaction of $3,723,440.00. Following the completion of the transaction, the chief executive officer now directly owns 65,602 shares of the company's stock, valued at approximately $34,895,015.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,635 shares of company stock worth $11,565,286. Insiders own 0.39% of the company's stock.
About Humana
(Get Rating)
Humana Inc engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts.
Featured Stories
- Get a free copy of the StockNews.com research report on Humana (HUM)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
